Could a cholesterol drug boost lung cancer treatment before surgery?
NCT ID NCT06385262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding the cholesterol-lowering drug alirocumab to standard chemotherapy and immunotherapy (cemiplimab) before surgery helps eliminate more cancer in people with stage 1B-3A non-small cell lung cancer. About 126 participants will be randomly assigned to receive either chemo plus cemiplimab or the same combination with alirocumab. The main goal is to see if the three-drug combo leads to a complete disappearance of cancer in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Alirocumab (a cholesterol-lowering drug) and cemiplimab (an immunotherapy) combined with standard chemotherapy
What this could lead to
If it works, this could point toward a more effective pre-surgery treatment for early-stage lung cancer, potentially increasing the chance of eliminating all cancer before surgery.
What could go wrong
This is a small, early-phase trial that is currently suspended, so results may not be conclusive. Adding alirocumab may not improve outcomes and could increase side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27710, United States